P35963 (POL_HV1Y2) Human immunodeficiency virus type 1 group M subtype B (isolate YU-2)(HIV-1)

Gag-Pol polyprotein UniProtKBInterProInteractive Modelling

1435 aa; Sequence (Fasta)

Available Structures

27 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
MDR769 HIV-1 protease complexed with RH/IN hepta-peptide Heteromer
489-1151
Assess
MDR769 HIV-1 protease complexed with RT/RH hepta-peptide Heteromer
489-1031
Assess
MDR769 HIV-1 protease complexed with MA/CA hepta-peptide Heteromer
130-587
Assess
MDR769 HIV-1 protease complexed with CA/p2 hepta-peptide Heteromer
361-587
Assess
MDR769 HIV-1 protease complexed with p2/NC hepta-peptide Heteromer
375-587
Assess
MDR769 HIV-1 protease complexed with p1/p6 hepta-peptide Heteromer
381-587
Assess
MDR769 HIV-1 protease complexed with NC/p1 hepta-peptide Heteromer
430-587
Assess
MDR769 HIV-1 protease complexed with PR/RT hepta-peptide Heteromer
489-591
Assess
MDR769 HIV-1 protease complexed with TF/PR hepta-peptide Heteromer
486-587
Assess
The structural and thermodynamic basis for the binding of TMC114, a next-generation HIV-1 protease …homo-2-mer489-587
PO4;ACT;017;
Assess
Stereoselective Synthesis, X-ray Analysis, and Biological Evaluation of a New Class of Lactam Based…homo-2-mer489-587
QG9;
Assess
Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variantshomo-2-mer489-587
Assess
Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variantshomo-2-mer489-587
Assess
Stereoselective Synthesis, X-ray Analysis, and Biological Evaluation of a New Class of Lactam Based…homo-2-mer489-587
QG8;
Assess
LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASEhomo-2-mer489-587
ACT;XN2;
Assess
HIV PR drug resistant patient's variant in complex with darunavirhomo-2-mer489-587
017;BME;
Assess
crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of HIV-1 p…homo-2-mer489-587
ACT;478;
Assess
LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASEhomo-2-mer489-587
ACT;MK1;
Assess
LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASEhomo-2-mer489-587
ACT;XN3;
Assess
Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variantshomo-2-mer489-587
Assess
Crystal Structures of Multidrug-Resistant Clinical Isolate 769 HIV-1 Protease Variantshomo-2-mer489-587
Assess
LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASEhomo-2-mer489-587
ACT;XN1;
Assess
SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (D FORM), NMR, REGULARIZE…homo-2-mer1148-1194
ZN;
Assess
SOLUTION STRUCTURE OF THE N-TERMINAL ZN BINDING DOMAIN OF HIV-1 INTEGRASE (E FORM), NMR, REGULARIZE…homo-2-mer1148-1194
ZN;
Assess
NMR Structure of the monomeric mutant C-terminal domain of HIV-1 Capsid in complex with stapled pep…monomer280-363
Assess
DYNAMICAL BEHAVIOR OF THE HIV-1 NUCLEOCAPSID PROTEIN; NMR, 30 STRUCTURESmonomer378-432
ZN;
Assess
NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop sl2 of the psi-RNA packaging sig…monomer378-432
ZN;
Assess

9 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6rwm.1.Ahomo-12-mer0.751148-1419
ZN;75.69
Assess
6rwl.1.Amonomer0.731148-1416
ZN;75.69
Assess
6rwl.1.Bmonomer0.731148-1419
ZN;75.69
Assess
6v3k.3.Ahomo-4-mer0.721170-1424
93.98
Assess
7t15.1.Ehomo-6-mer0.71133-352
84.42
Assess
7sep.1.Ahomo-2-mer0.71591-1140
97.31
Assess
1l6n.1.Amonomer0.712-283
96.47
Assess
5u1c.1.Ahomo-4-mer0.701170-1416
93.61
Assess
7asl.1.Ahomo-18-mer0.67143-377
99.15
Assess